Avenue Therapeutics (ATXI) director and 10% owner receives 111,209-share stock dividend

Rhea-AI Filing Summary

Avenue Therapeutics, Inc. reported an insider stock award linked to preferred stock dividends. A reporting person who is both a director and a 10% owner received 111,209 shares of common stock on 01/02/2026 at a price of $0. These shares were granted as the 2025 annual dividend on the holder’s Class A Preferred Stock, which is entitled to a 2.5% annual dividend based on Avenue’s fully diluted outstanding capitalization on December 31. After this grant, the reporting person beneficially owned 439,733 shares of Avenue Therapeutics common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fortress Biotech, Inc.

(Last) (First) (Middle)

1111 KANE CONCOURSE SUITE 301

(Street)

BAY HARBOR ISLANDS FL 33154

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVENUE THERAPEUTICS, INC. [ ATXI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK, PAR VALUE $0.0001	01/02/2026		A		111,209(1)	A	$0	439,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 111,209 shares were granted by the Issuer to the reporting Person for the 2025 annual dividend.

	/s/ Samuel Berry, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Avenue Therapeutics (ATXI) report in this filing?

The filing reports that a director and 10% owner received 111,209 shares of Avenue Therapeutics common stock on 01/02/2026 as part of an annual stock dividend.

Why did the Avenue Therapeutics (ATXI) insider receive 111,209 shares?

The insider received 111,209 shares because their Class A Preferred Stock is entitled to an annual dividend equal to 2.5% of Avenue’s fully diluted outstanding capitalization on December 31, and these shares represent the 2025 annual dividend.

What was the reported price for the Avenue Therapeutics (ATXI) insider share grant?

The 111,209 Avenue Therapeutics common shares were reported with a transaction price of $0, indicating they were issued as a stock dividend rather than a market purchase.

How many Avenue Therapeutics (ATXI) shares does the insider own after this transaction?

Following the reported transaction, the insider beneficially owned 439,733 shares of Avenue Therapeutics common stock, held in direct ownership.

What is the relationship of the reporting person to Avenue Therapeutics (ATXI)?

The reporting person is identified as both a director and a 10% owner of Avenue Therapeutics, Inc.

Was this Avenue Therapeutics (ATXI) insider transaction reported under a Rule 10b5-1 plan?

The form includes a checkbox for transactions made under a Rule 10b5-1(c) trading plan, but the excerpt does not indicate that this box was checked for the reported transaction.